Tick-borne Encephalitis
📧 Sign up to get email alerts when something new happens for Tick-borne Encephalitis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: Tick-borne Encephalitis Virus Research in Limousin
A Limousin-based clinical trial investigating tick-borne encephalitis virus research has completed.
-
CLINICAL_TRIALS trial_result · 2024-12-13Clinical Trial Update: Management of Tick-borne Encephalitis
This document reports that a clinical trial evaluating management of tick-borne encephalitis has completed. It provides outcomes and implica…
-
CLINICAL_TRIALS trial_result · 2024-01-19Clinical Trial Update: Immunogenicity, Safety and Interchangeability of Two Tbe Vaccines Administered According to a Conventional Schedule in Children [Phase 3]
Phase 3 clinical trial update assessing immunogenicity, safety, and interchangeability of two tick-borne encephalitis vaccines given on a co…
-
CLINICAL_TRIALS trial_result · 2023-11-22Clinical Trial Update: Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Tick-Borne Encephalitis (TBE) Vaccine in Healthy Japanese Participants 1 Year of Age and Older [Phase 3]
A Phase 3 trial evaluating a Tick-Borne Encephalitis vaccine in healthy Japanese participants aged 1 year and older has completed with resul…
-
CLINICAL_TRIALS trial_result · 2023-11-18Clinical Trial Update: Primary TBE Vaccination for the Elderly [Phase 4]
Phase 4 trial update on primary vaccination against tick-borne encephalitis in the elderly.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-02-10Clinical Trial Update: New Study - Humoral Response to Tick-borne Encephalitis Vaccine in Elderly [Phase 2, Phase 3]
A phase 2/3 study evaluated the humoral immune response to a Tick-borne Encephalitis vaccine in elderly participants and has completed.
-
CLINICAL_TRIALS trial_result · 2021-01-22Clinical Trial Update: TBE Seropersistence up to 10 Years After First Booster in Adults [Phase 4]
Phase 4 trial update reporting seropersistence of Tick-borne Encephalitis antibodies up to 10 years after first booster in adults.
-
CLINICAL_TRIALS trial_result · 2020-07-14Clinical Trial Update: Humoral and Cellular Immunity for TBE Vaccination in Allogeneic HSCT Recipients [Phase 2]
Phase 2 trial evaluating humoral and cellular immunity of Tick Borne Encephalitis vaccination in allogeneic hematopoietic stem cell transpla…
-
CLINICAL_TRIALS trial_result · 2019-10-25Clinical Trial Update: TBE (Tick-borne Encephalitis) Vaccination in Allergic Patients [Phase 4]
Phase 4 clinical trial evaluating tick-borne encephalitis vaccination in allergic patients has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2019-09-10Clinical Trial Update: Application of a TBE-Vaccine in Obese Persons [Phase 4]
Phase 4 clinical trial update examining a tick-borne encephalitis vaccine in obese individuals.
-
CLINICAL_TRIALS trial_result · 2018-08-31Clinical Trial Update: Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne Encephalitis Vaccine in Adults Who Received 1 of 3 Different Primary Vaccination Schedules [Phase 4]
Phase 4 study evaluating long-term immunogenicity up to 10 years after first booster in adults across three primary vaccination schedules fo…
-
CLINICAL_TRIALS trial_result · 2018-08-03Clinical Trial Update: Cervicovaginal Immune Responses to 3 Deltoid or Thigh Intramuscular (IM) TicoVac [Phase 4]
Phase 4 trial update on cervicovaginal immune responses to intramuscular TicoVac dosing; study completed.
-
CLINICAL_TRIALS trial_result · 2018-07-05Clinical Trial Update: Vaccine Study for Tick-Borne Encephalitis Virus (TBEV) [Phase 2]
Phase 2 trial of a tick-borne encephalitis vaccine candidate sponsored by NIAID was terminated, with results posted in 2018.
-
CLINICAL_TRIALS trial_result · 2018-05-18Clinical Trial Update: Comparison of Vaccination Routes: Subcutaneous Versus Intramuscular Application of FSME-Immun® [Phase 4]
A Phase 4 study comparing subcutaneous versus intramuscular administration of FSME-Immun for Tick-borne encephalitis; results were posted in…
-
CLINICAL_TRIALS trial_result · 2015-11-18Clinical Trial Update: Humoral Response to Tick-borne Encephalitis Vaccine in Elderly [Phase 2, Phase 3]
This update reports humoral immune response results from phase 2 and phase 3 trials of a Tick-borne Encephalitis vaccine in elderly adults.
-
CLINICAL_TRIALS trial_result · 2015-05-21Clinical Trial Update: Safety and Immunogenicity Study of 3 Vaccinations With TICOVAC in 2 Dosages in Healthy Children Aged Between 6 Months and 3 Years [Phase 2, Phase 3]
Pfizer's TICOVAC was evaluated in healthy children aged 6 months to 3 years across Phase 2/3 for safety and immunogenicity after three vacci…
-
CLINICAL_TRIALS trial_result · 2015-05-21Clinical Trial Update: Safety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 Years [Phase 3]
Phase 3 safety study of FSME-IMMUN NEW in healthy children and adolescents aged 1 to 15 years completed.
-
CLINICAL_TRIALS trial_result · 2015-05-21Clinical Trial Update: Immunogenicity and Safety Study of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated According to a Rapid Immunization Schedule (Follow-up to Study 225) [Phase 4]
Phase 4 trial assessing immunogenicity and safety of a third FSME-IMMUN booster in adults previously vaccinated according to a rapid immuniz…
-
CLINICAL_TRIALS trial_result · 2015-05-21Clinical Trial Update: FSME IMMUN NEW Follow-up to Study 199 in Children Aged 1 to 6 Years [Phase 2]
Phase 2 follow-up study of FSME IMMUN NEW in children aged 1 to 6 years for tick-borne encephalitis has completed.
-
CLINICAL_TRIALS trial_result · 2015-05-21Clinical Trial Update: Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 6 to 16 Years. [Phase 2]
Phase 2 dose-finding study evaluating the safety and immunogenicity of two vaccinations with FSME IMMUN NEW in healthy volunteers aged 6 to …
-
CLINICAL_TRIALS trial_result · 2015-05-21Clinical Trial Update: FSME IMMUN NEW Follow-up to Study 205 in Children Aged 6 to 16 Years [Phase 2]
Pfizer's FSME IMMUN NEW completed a Phase 2 follow-up study (Study 205) in children aged 6 to 16 years for tick-borne encephalitis. The tria…
-
CLINICAL_TRIALS trial_result · 2015-05-21Clinical Trial Update: FSME IMMUN NEW Follow-up to Study 208 in Volunteers Aged 16 to 66 Years [Phase 3]
A Phase 3 follow-up study (Study 208) of FSME Immun NEW in volunteers aged 16 to 66 years has completed.
-
CLINICAL_TRIALS trial_result · 2015-05-21Clinical Trial Update: Immunogenicity and Safety Study of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years [Phase 4]
Phase 4 clinical trial evaluating the immunogenicity and safety of a rapid immunization schedule using FSME-Immun 0.5 mL in healthy adults a…
-
CLINICAL_TRIALS trial_result · 2015-05-21Clinical Trial Update: Study to Investigate the Seropersistence of TBE Virus Antibodies Approx. 3 Years After a Booster Vaccination With FSME-IMMUN 0.25 mL JUNIOR in Children
The study evaluated the persistence of TBE virus antibodies about three years after a booster dose of FSME-Immun Junior in children. The tri…
-
CLINICAL_TRIALS trial_result · 2015-05-21Clinical Trial Update: Safety Study in Volunteers From 16 to 65 Years of Age: FSME IMMUN NEW vs. ENCEPUR [Phase 3]
Phase 3 safety study comparing FSME IMMUN NEW with ENCEPUR in volunteers aged 16 to 65 for tick-borne encephalitis; the trial status is comp…